Talking Euretina

Artificial intelligence is rapidly reshaping retina care — but where does it truly add value in daily practice? Professors Tien Wong and Daniel Ting join Stela Vujosevic to explore how AI is moving beyond screening into risk stratification, clinical decision support, and home monitoring. From infrastructure challenges to real-world implementation, this episode offers practical insights for retina specialists preparing for an AI-enabled future

Artificial intelligence is rapidly reshaping how we screen, classify, and treat diabetic retinal disease. Professor Aude Couturier, Professor Edoardo Midena, and Professor Reinier Schlingemann discuss real-world AI applications in diabetic retinopathy — from population screening and imaging biomarkers to phenotyping and precision treatment in diabetic macular oedema

What drives leading retina specialists to trade the clinic for corporate innovation? In this episode, Euretina Board member Kourous Rezaei speaks with Jay Duker (CEO, Eyepoint), Sascha Fauser (SVP, Roche), and Marion Munk (CSO, Gutblick Group; CMO, Isarna Therapeutics) about their transitions from clinical practice to industry. Together they share insights on leadership, research, and the evolving relationship between academia and biotechnology in shaping the future of retinal therapeutics

In this episode Professors Dean Eliott, Grazia Pertile, and José García-Arumí join chair Kourous Rezaei to explore how surgical mastery is built through intuition, preparation, and reflection. They share practical insights on mentorship, focus, teamwork, and managing stressful cases — from avoiding coffee before surgery to resetting after complications — revealing that great surgeons are defined not just by skill, but by judgment, patience, and care for the patient

In this first-ever debate edition of Talking Euretina, Dr Rumana Hussain (Liverpool Ocular Oncology Centre) introduces Professors Arun Singh (Cole Eye Institute, Cleveland Clinic), Heinrich Heimann (Liverpool Ocular Oncology Service) and Bertil Damato (Moorfields Eye Hospital) as they debate one of ocular oncology’s most enduring questions — when to operate on small choroidal melanomas. The panel examines diagnostic uncertainty, genetic risk and patient choice in determining when to treat.